NEW SUMMER SERIES – Spotlight on practicalities of prescribing SGLT2 inhibitors in Type 2 Diabetes management
Funded by A. Menarini Farmaceutica Internazionale SRL. Full disclaimer of involvement below.
There is a big unmet need in terms of translating current evidence and guidance into front line clinical practice.
The overarching objective is to improve the knowledge and confidence of primary care health practitioners in the management of type 2 diabetic patients by offering practical, case-based guidance from our panel of experts. In addition you will be introduced to two simple and effective tools to help during consultations.
Part 2 : Evidence-informed practical guidance for safe and appropriate prescribing of SGLT2is in type 2 diabetes
Wednesday 21st August, 19:00 hours
Webinar Login
This educational programme has been supported by:
A. Menarini Farmaceutica Internazionale
SRL (Menarini) have provided funding support
towards this independent programme. This is
a promotional meeting for GB-registered
healthcare professionals only. Menarini
products may be discussed during the
meeting.
Menarini have had no input into the agenda,
choice of speaker or content of the meeting
but have certified the slides for compliance
with the pharmaceutical industry code of
practice.
The content, opinions and statements made in this programme are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board.
PP-IN-UK-2056 | August 2024
